title: Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
authors.affiliation: Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.
authors.forename: T
authors.initials: T
authors.lastname: van Gelder
authors.forename: R
authors.initials: R
authors.lastname: Zietse
authors.forename: J N
authors.initials: JN
authors.lastname: Yzermans
authors.forename: J
authors.initials: J
authors.lastname: Rischen-Vos
authors.forename: L M
authors.initials: LM
authors.lastname: Vaessen
authors.forename: W
authors.initials: W
authors.lastname: Weimar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum; D016572:Cyclosporine / Q000627:therapeutic use; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008775:Methylprednisolone / Q000627:therapeutic use; D010919:Placebos; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D010919:Placebos; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D011241:Prednisone; D008775:Methylprednisolone